Company intelligence / Profile preview

RENOVA

Carlsbad, California, United States

Ownership: Private
Development stage: Other

Overview

Renova has completed a Phase 2 trial for heart failure with its lead gene therapy RT-100 (AC6 gene transfer), showing increased heart function over optimal standard therapy. Its gene therapy for type 2 diabetes (RT-200/Ucn2) has completed promising preclinical studies and is preparing to enter clinical trials. It holds MHRA Innovation Passports in the UK for both indications as of 2022

Therapeutic areas: EndocrinologyMetabolic DisordersCardiovascular
Modalities: Gene therapy
Industry: Biotech

Partnerships

National Institutes of Health (US public-private partnership, clinical trials support)No current major pharma partnerships publicly disclosed.

Beyond the preview

Go deeper on RENOVA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RENOVA.

Explore the full profile